After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...